In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Soligenix Inc (OTC:SNGX) with a $3.00 price …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Biolinerx (NASDAQ:BLRX) with a $7.00 price target, following the …
In a research note released yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (NYSE:SYN) with a $6 price target …
In a research note published yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) and an $8 price …
In a research note released Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a $24 price target, following today’s FDA approval …
In a research report released September 5, Maxim Group analyst Jason Kolbert upgraded shares of IntelliPharmaCeutics (NASDAQ:IPCI) from Hold to Buy rating and raised his price target to $7.00 (from $3.
In a research report released today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Soligenix (SNGX) with a $3 price target, …
In a research note released today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Momenta Pharmaceuticals (NASDAQ:MNTA) with a $17 price …
In a research report released today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Cesca Therapeutics (NASDAQ: KOOL) with a $7 price …
In a research note published this morning, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on DelMar Pharmaceuticals (NASDAQ: DMPI) with an …
